Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
Wall Street Recommends Buying These 2 Falling Knives
05:34pm, Monday, 13'th Apr 2020
Wall Street Recommends Buying These 2 Falling Knives, Stocks: STML,KALV, release date:Apr 13, 2020
Wall Street Recommends Buying These 2 Falliing Knives
05:04pm, Monday, 13'th Apr 2020
Wall Street Recommends Buying These 2 Falliing Knives, Stocks: STML,KALV, release date:Apr 13, 2020
Kalvista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by Zacks Investment Research
05:38am, Monday, 13'th Apr 2020
Kalvista Pharmaceuticals (NASDAQ:KALV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports. According to
Franklin Resources Inc. Invests $5.05 Million in Kalvista Pharmaceuticals Inc (NASDAQ:KALV)
10:36am, Saturday, 11'th Apr 2020
Franklin Resources Inc. acquired a new position in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commis
KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference
11:00am, Thursday, 09'th Apr 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc
Needham Remains a Buy on KalVista Pharmaceuticals (KALV)
05:10pm, Tuesday, 07'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price
KalVista Pharmaceuticals Provides Operational and Financial Update
11:00am, Tuesday, 07'th Apr 2020
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announce
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
KalVista Pharmaceuticals (KALV) Receives a Buy from Needham
08:12pm, Tuesday, 10'th Mar 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on KalVista Pharmaceuticals (
KALV
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Monday at $1
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
11:30am, Tuesday, 10'th Mar 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provide
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
07:25pm, Friday, 21'st Feb 2020
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
03:22pm, Friday, 21'st Feb 2020
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
KalVista Pharmaceuticals to Present at SVB Leerink 9th Annual Global Healthcare Conference
12:30pm, Wednesday, 19'th Feb 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc
